Abstract
Background
This study was designed to investigate the clinical characteristics correlated with serum CA19-9 elevation in primary mucinous ovarian tumors and to evaluate the role of serum CA19-9 in predicting borderline or malignant tumors.
Material/Methods
We retrospectively identified 27 women with pathologically-confirmed primary ovarian mucinous neoplasms (16 borderline and 11 malignant), who had been preoperatively checked for serum CA19-9 and CA125 levels. The control group was established by 1:2 matching for age among all women with pathologically-confirmed benign mucinous tumors over the same time period. The associations of the serum CA19-9 elevation and clinical characteristics, including tumor pathology, were evaluated.
Results
Serum CA19-9 was more frequently elevated in borderline or malignant than benign tumors (57.9% vs. 16.7%, P=0.001), although the mean value of serum CA19-9 was not significantly different among histological subtypes. CA19-9 elevation was correlated with large tumor size (largest diameter ≥15 cm; p=0.028), serum CA125 elevation (p=0.006), and tumor pathology (borderline or malignant tumors; p=0.001). Other clinical characteristics, including parity, menopause, bilateral tumor involvement, and torsion were not correlated with CA19-9 elevation. Multivariate analysis revealed that tumor pathology was the only independent factor for CA19-9 elevation in primary ovarian mucinous tumors (odds ratio 3.842, 95% CI 1.277–11.558, p=0.017). Interestingly, subgroup analysis in women with normal serum CA 125 level revealed that CA19-9 was significantly correlated with borderline and malignant tumors but not with benign tumors (odds ratio 6.3, 95% CI 1.438–19.648, p=0.014).
Conclusions
Serum CA19-9 can be a useful complementary marker in differentiating benign from borderline or malignant mucinous tumors in the ovaries, particularly when serum CA125 level is not elevated.
MeSH Keywords: CA-19-9 Antigen, Cystadenoma, Mucinous, Ovary, Tumor Markers, Biological
Background
CA19-9 is a monosialoganglioside, which is associated with various types of mucinous tumors in the gastrointestinal tract, such as in the pancreas and biliary tract [1–3]. Serum CA19-9 plays an important role in the diagnosis and prognostication of colorectal, pancreatic, and biliary tract cancers [4–6].
In the gastrointestinal tract and ovaries, primary tumors are associated with CA19-9 secretion. There have been a number of studies suggesting that serum CA19-9 level might be a useful marker in diagnosis of benign dermoid cyst [3,7]. In those studies, large tumor size, bilateral tumor involvement, and tumor torsion were correlated with serum CA19-9 elevation [3,7].
However, there have been limited reports of CA19-9 as a diagnostic marker in ovarian mucinous tumors [8]. Although many gynecologic oncologists are using serum CA19-9 level as a preoperative marker in the investigation of women with an ovarian mass, evidence is still insufficient. In addition, differentiation of malignant tumors from benign tumors will be more challenging if the role of CA125 as a screening tool is controversial in ovarian malignancy [9]. Serum CA125 is frequently elevated in benign conditions, including pregnancy, endometriosis, and pelvic inflammatory disease, as well as in malignant disorders. Moreover, a number of studies suggest that CA125 is not elevated in most primary ovarian mucinous neoplasms [10–13].
Therefore, we investigated the clinical characteristics correlated with serum CA19-9 elevation and evaluated the role of serum CA19-9 in differentiating benign from borderline or malignant mucinous tumors in the ovaries.
Material and Methods
From 2001 to 2011 in Hallym Medical University Hospital, a total of 149 women with pathologically-confirmed primary ovarian mucinous tumors were preoperatively checked for serum CA19-9 and CA125 levels. Of those, 16 cases were borderline tumors and 11 cases were malignant tumors. All the patients with malignant mucinous tumors were in Stage 1 or 2. Among 122 women with pathologically-confirmed benign mucinous cystadenomas in the ovaries, the control group was established by 1:2 matching for age to complement the small sample size of borderline or malignant tumors compared to benign tumors. Our study was approved by the institutional review board of our hospital. Patients with benign disease in the gastrointestinal tract, such as in the pancreas and gall bladder, and patients with other co-existing malignant tumors, were excluded from the study group.
Patient characteristics (age at operation, parity, and menopause), ultrasonographic (US) findings of the lesion (the largest diameter and site of the lesion), preoperative level of serum tumor markers (CA125 and CA19-9), and existence of torsion were retrieved from medical records and pathology reports. The serum level of CA 19-9 and CA 125 were determined by radioimmunoassay by using the Modular Analytics E 170 module (Roche Laboratory systems, Mannheim, Germany). The cut-off values for CA19-9 and CA 125 are 37 U/mL and 35 U/mL, respectively.
Statistical analyses were performed using SPSS for Windows (version 18.0, SPSS Inc.). Dichotomous variables were compared by Fisher’s exact test or chi-square test. Continuous variables were compared by t-test. Multivariate analysis was performed using binary logistic regression. The hazard ratio (HR) and 95% confidence intervals (CI) were calculated. For all statistical tests, P value less than 0.05 was considered significant.
Results
Serum CA19-9 was elevated in the ovaries in 16.7%, 56.3%, and 45.5% of benign, borderline, and malignant mucinous tumors, respectively (Table 1). In contrast, serum CA125 was elevated in only 27.3% of cases with malignant mucinous tumors in the ovaries. Although the mean value of serum CA19-9 was not significantly different among histological subtypes (P=0.774), serum CA19-9 was more frequently elevated in borderline or malignant mucinous tumors than in benign tumors (57.9% vs. 16.7%, P=0.001).
Table 1.
Serum CA19-9 and CA125 levels in histological subtypes of primary ovarian mucinous tumor.
| Tumor subtype | CA19-9 | CA125 | ||
|---|---|---|---|---|
| Elevated CA19-9 N (%) | Mean (range) (U/ml) | Elevated CA125 N (%) | Mean (range) (U/ml) | |
| Benign (N=54) | 9 (16.7) | 127.8 (3.24~6000.00) | 7 (13.0) | 22.87 (4.51~234.61) |
| Borderline (N=16) | 9 (56.3) | 253.8 (4.95~1828.00) | 8 (50.0) | 52.8 (8.61~244.17) |
| Malignant (N=11) | 5 (45.5) | 107.5 (6.23~548.00) | 3 (27.3) | 45.8 (6.80~238.17) |
Clinical characteristics in association with serum CA19-9 elevation in women with primary ovarian mucinous tumors are described in Table 2. Specifically, the largest diameter of tumor (≥15 cm in US finding), serum CA125 elevation, and tumor pathology (borderline or malignant) were correlated with elevated serum CA19-9 levels. However, torsion, bilateral involvement of tumor, and other patient characteristics, including parity and menopause, were not correlated with serum CA19-9 elevation. Multivariate analysis revealed that tumor pathology (borderline or malignant) was the only independent factor for serum CA19-9 elevation in primary ovarian mucinous tumors (odds ratio [OR] 3.842, 95% CI 1.277–11.558, p=0.017) (Table 3).
Table 2.
Clinical characteristics correlating with serum CA19-9 elevation in patients with mucinous tumors.
| CA19-9 normal (N=58) | CA19-9 elevated (N=23) | P value | |
|---|---|---|---|
| Patient characteristics | |||
| Age, years | 42.3 (±2.27) | 46.7 (±4.31) | 0.329 |
| Parity | 2.8 (±0.34) | 2.6 (±0.55) | 0.759 |
| Menopause | 0.400 | ||
| No | 46 (79.3) | 17 (73.9) | |
| Yes | 12 (20.7) | 6 (26.1) | |
| Serum CA125 | 0.006* | ||
| <35 U/ml | 50 (86.2) | 13 (56.5) | |
| ≥35 U/ml | 8 (13.8) | 10 (43.5) | |
| Tumor characteristics | |||
| Tumor size (largest diameter) | 0.028* | ||
| <15 cm | 38 (65.5) | 9 (39.1) | |
| ≥15 cm | 20 (34.5) | 14 (60.9) | |
| Bilateral involvement | 0.610 | ||
| No | 48 (82.8) | 19 (82.6) | |
| Yes | 10 (17.2) | 4 (17.4) | |
| Torsion | 1.000 | ||
| No | 55 (94.8) | 22 (95.7) | |
| Yes | 3 (5.2) | 1 (4.3) | |
| Pathology | 0.001* | ||
| Benign | 45 (77.6) | 9 (39.1) | |
| Borderline or malignant | 13 (22.4) | 14 (60.9) | |
Data are presented as mean ±SD or absolute numbers (%).
P<0.05.
Table 3.
Multivariate analysis for risk factors of serum CA19-9 elevation in patients with mucinous tumors.
| Factors | Odds ratio (95% CI**) | P value |
|---|---|---|
| Pathology (borderline or malignant tumor) | 3.842 (1.277–11.558) | 0.017* |
| CA125 elevated | 2.768 (0.807–9.494) | 0.106 |
| Tumor size (largest diameter ≥15 cm) | 1.777 (0.579–5.451) | 0.315 |
P<0.05;
CI – confidence interval.
Interestingly, subgroup analysis in women with normal serum CA 125 level revealed that serum CA19-9 elevation was significantly correlated with borderline or malignant tumors than benign (12.8% vs. 43.8%, p=0.014) (Table 4). Odds ratio for serum CA19-9 elevation was 6.3 (95% CI 1.438–19.648). In other words, negative predictive value and positive predictive value of CA19-9 was 87.2% and 43.8%, respectively, for cancer discrimination in patients with normal CA125.
Table 4.
Relationship between serum CA19-9 elevation and tumor pathology of women with primary ovarian mucinous tumors and normal serum CA 125 level.
| Benign (N=47) | Borderline or malignant (N=16) | P value | Odds ratio | 95% CI** | |
|---|---|---|---|---|---|
| CA19-9 | 0.014* | 6.3 | 1.438–19.648 | ||
| Normal | 41 (87.2%) | 9 (56.3%) | |||
| Elevated | 6 (12.8%) | 7 (43.8%) |
P<0.05;
CI – confidence interval.
Discussion
CA19-9 is a sialylated Lewis A antigen, which is associated with mucins in gastrointestinal adenocarcinomas and also is frequently expressed in mucinous tumors in the ovaries [14]. Although CA19-9 is recognized as a useful diagnostic marker in various types of mucinous tumors in the gastrointestinal tract (e.g., in the pancreas and biliary tree), there have been limited reports of CA19-9 as a diagnostic marker in ovarian mucinous tumors [3,7,8].
Primary mucinous tumors, which account for approximately 12–15% of all ovarian tumors, can be subdivided into 2 distinct histogenetic types: the much more common intestinal (or non-specific) type and the less common Müllerian (or endocervical) type [15]. Therefore, CA125, which is secreted by mainly Müllerian origin tissue, cannot be a major tumor marker in mucinous tumors of the ovaries. Pathologically, primary ovarian mucinous tumors are classified as benign, borderline (mucinous tumor of low malignant potential), or malignant tumors [16]. Although 75% of primary mucinous tumors are benign, the other 10% and 15% are comprised of borderline and malignant tumors, respectively [16].
According to a recent model for ovarian carcinogenesis, ovarian neoplasms can be divided into type I and type II, and each should be considered as a different disease [17,18]. Type I tumors, including low-grade serous, mucinous, endometrioid, clear cell, and transitional cell carcinomas, are often confined to the ovary at the time of diagnosis, with a stable genome and without TP53 mutations [19,20]. In contrast, type II tumors, including high-grade serous carcinomas, undifferentiated carcinomas, and carcinosarcomas, are more aggressive and genetically highly unstable [19,21–23]. Actually, the behavior of mucinous ovarian carcinoma is different from that of serous ovarian carcinoma.
Despite a relatively good prognosis in early-stage disease, mucinous ovarian cancers are frequently associated with poorer response to platinum/taxane chemotherapies, and poorer survival, compared to serous ovarian cancers [24–26]. In addition, mucinous borderline ovarian tumors, which are generally characterized as having low malignant potential without obvious stromal invasion, may present with peritoneal implants, lymph node metastases, and recurrence after the resection [16,27,28]. However, in contrast to serous tumors, differential diagnosis of benign from borderline or malignant tumors is more challenging in mucinous tumors because of their typical large size and the great variation in the degree of differentiation of individual tumors [29]. Although magnetic resonance imaging (MRI) has recently been suggested as a useful diagnostic tool for mucinous borderline or malignant tumors, considering its cost-effectiveness, the role of MRI is still questionable [30–33]. Moreover, serum CA 125 level, which is a typical tumor marker in serous-type ovarian cancer, is less frequently elevated in mucinous tumors than in non-mucinous tumors [10,11,34,35]. Therefore, verification of CA19-9 as an effective diagnostic marker is important.
In our results, serum CA19-9 was frequently elevated in primary ovarian mucinous tumors. Moreover, borderline and malignant mucinous tumors, but not benign mucinous tumors, were significantly associated with serum CA19-9 elevation. It might be natural that serum CA19-9, which is a sialylated Lewis A antigen associated with mucins, is frequently elevated in primary mucinous ovarian tumors. The principal mechanism of the elevation of CA19-9 in ovarian cysts is well-documented in a number of studies of mature cystic teratomas. For instance, Ito et al. demonstrated the presence of CA19-9 in the bronchial mucosa and glands of ovarian mature cystic teratoma by immunohistochemical staining [36]. They also revealed the secretion of CA19-9 into the cystic cavity of the lesion [36]. Considering to those findings, the leakage of CA19-9 from the cystic cavity into the blood stream might be a main mechanism of serum CA19-9 elevation [36].
We can predict that probable conditions of leakage into the blood stream, such as a larger size tumor, bilateral involvement of the tumor, and tumor torsion, may be correlated with serum CA19-9 elevation. Several studies have described the clinical characteristics correlated with serum CA19-9 elevation in women with primary ovarian mature cystic teratomas. Kyung et al. reported that CA19-9 elevation was correlated with larger tumor size and higher rate of ovarian torsion in ovarian mature cystic teratomas [7]. Similarly, Umin et al. demonstrated significant correlation between serum CA19-9 levels and larger tumor size, although they failed to show a positive relationship between bilateral tumor involvement and serum CA19-9 levels [37]. Likewise, Cho et al. reported that serum CA19-9 elevation was associated with larger tumor size and presence of a fat component in ovarian mature cystic teratomas [38]. Moreover, they suggested that simultaneous elevation of serum CA125 and CA19-9 was associated with a higher cancer risk (p<0.001; OR: 23.7; 95% CI: 8.863–63.576) than single elevation of serum CA 19-9 [38]. In our results, clinical characteristics associated with serum CA19-9 were not the bilateral tumor involvement or existence of torsion, but rather larger tumor size, serum CA125 elevation, and tumor pathology (borderline or malignant). In agreement with results of prior studies, we found that the elevation of serum CA19-9 in ovarian mucinous tumors was significantly correlated with larger tumor size, with leakage as a likely mechanism. But more importantly, we should focus on the fact that tumor pathology (borderline or malignant) was the only independent risk factor for serum CA19-9 elevation in primary ovarian mucinous tumors (OR 3.842, 95% CI 1.277–11.558, p=0.017). Subgroup analysis in women with normal serum CA 125 level showed that cancer risk (≥ borderline) in women with serum CA19-9 elevation is 6.3 times higher than in those with normal serum CA19-9 level (95% CI 1.438–19.648, p=0.014), which is comparable to results of Cho et al. [38].
As previously mentioned, serum CA19-9 is a well-recognized tumor marker in diagnosis and in predicting prognosis of various types of mucinous tumors in the gastrointestinal tract [3,7,8,39]. There is little published evidence of the potential of CA19-9 as a preoperative diagnostic tool in ovarian cancer. The only retrospective study is by Paul et al., which failed to show a significant correlation between serum CA19-9 elevation and histologic subtype of primary ovarian mucinous tumors (benign 27% vs. borderline 38% vs. malignant 40%, p=0.32) [8]. Although they found a weak but statistically significant correlation between tumor size and serum CA19-9 level (Spearman’s rank correlation coefficient=0.17, p=0.04), they concluded that serum CA19-9 cannot be used to predict histologic subtype of mucinous tumors [8]. In contrast, serum CA19-9 showed promise in our results. Serum CA19-9 was elevated more frequently in borderline and malignant mucinous tumors, and multivariate analysis revealed that tumor pathology was the only independent correlating factor for serum CA19-9 elevation, regardless of tumor size and serum CA125 elevation. Particularly, subgroup analysis in women with normal serum CA 125 level showed that cancer risk (≥ borderline) in women with serum CA19-9 elevation is 6.3 times higher than in those without elevated levels of CA19-9.
Conclusions
Serum CA19-9, which is frequently elevated in primary ovarian mucinous tumors, can be a useful marker in predicting malignancy, particularly when serum CA125 level is not elevated. This is the first study suggesting a possible role of serum CA19-9 in diagnosis of borderline or malignant ovarian tumors, despite several weaknesses, including retrospective design and a small number of subjects. To clarify the diagnostic role of serum CA19-9 in discrimination of borderline and malignant tumors from benign mucinous ovarian tumors, more large-scale study will be required in the near future.
Footnotes
Source of support: Departmental sources
References
- 1.Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia. 2003;58:667–72. [PubMed] [Google Scholar]
- 2.Scharl A, Crombach G, Vierbuchen M, et al. Antigen CA 19-9: presence in mucosa of nondiseased mullerian duct derivatives and marker for differentiation in their carcinomas. Obstet Gynecol. 1991;77:580–85. [PubMed] [Google Scholar]
- 3.Dede M, Gungor S, Yenen MC, et al. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer. 2006;16:189–93. doi: 10.1111/j.1525-1438.2006.00284.x. [DOI] [PubMed] [Google Scholar]
- 4.Wang WS, Lin JK, Chiou TJ, et al. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 2002;49:160–64. [PubMed] [Google Scholar]
- 5.Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–69. doi: 10.1016/j.ejso.2004.09.007. [DOI] [PubMed] [Google Scholar]
- 6.Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18:530–38. doi: 10.1097/PPO.0b013e31827654ea. [DOI] [PubMed] [Google Scholar]
- 7.Kyung MS, Choi JS, Hong SH, et al. Elevated CA 19-9 levels in mature cystic teratoma of the ovary. Int J Biol Markers. 2009;24:52–56. doi: 10.1177/172460080902400108. [DOI] [PubMed] [Google Scholar]
- 8.Kelly PJ, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol. 2010;63:169–73. doi: 10.1136/jcp.2009.072355. [DOI] [PubMed] [Google Scholar]
- 9.Berek JS, Bast RC., Jr Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76:2092–96. doi: 10.1002/1097-0142(19951115)76:10+<2092::aid-cncr2820761331>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
- 10.Bast RC, Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–87. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
- 11.Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 1992;44:147–54. doi: 10.1016/0090-8258(92)90030-m. [DOI] [PubMed] [Google Scholar]
- 12.Zorn KK, Tian C, McGuire WP, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 2009;115:1028–35. doi: 10.1002/cncr.24084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lu D, Kuhn E, Bristow RE, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011;122:560–66. doi: 10.1016/j.ygyno.2011.05.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267–77. doi: 10.1016/j.ygyno.2005.06.040. [DOI] [PubMed] [Google Scholar]
- 15.Kelly PJ, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol. 2010;63(2):169–73. doi: 10.1136/jcp.2009.072355. [DOI] [PubMed] [Google Scholar]
- 16.Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol. 2005;24:4–25. [PubMed] [Google Scholar]
- 17.Landen CN, Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26:995–1005. doi: 10.1200/JCO.2006.07.9970. [DOI] [PubMed] [Google Scholar]
- 18.Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–18. doi: 10.1016/s0002-9440(10)63708-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261. doi: 10.1155/2014/934261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigm. Hum Pathol. 2011;42(7):918–31. doi: 10.1016/j.humpath.2011.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14–25. doi: 10.1002/ijc.20408. [DOI] [PubMed] [Google Scholar]
- 22.Salani R, Kurman RJ, Giuntoli R, II, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18:487–91. doi: 10.1111/j.1525-1438.2007.01039.x. [DOI] [PubMed] [Google Scholar]
- 23.Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. doi: 10.1146/annurev.pathol.4.110807.092246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.International Collaborative Ovarian Neoplasm G. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–15. doi: 10.1016/S0140-6736(02)09738-6. [DOI] [PubMed] [Google Scholar]
- 25.Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:945–52. doi: 10.1111/IGC.0b013e3181dd0110. [DOI] [PubMed] [Google Scholar]
- 26.Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J Clin Pathol. 2012;65:580–84. doi: 10.1136/jclinpath-2011-200320. [DOI] [PubMed] [Google Scholar]
- 27.Lalwani N, Shanbhogue AK, Vikram R, et al. Current update on borderline ovarian neoplasms. Am J Roentgenol. 2010;194:330–36. doi: 10.2214/AJR.09.3936. [DOI] [PubMed] [Google Scholar]
- 28.Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973;31:1031–45. doi: 10.1002/1097-0142(197305)31:5<1031::aid-cncr2820310501>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
- 29.Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139–52. doi: 10.1097/00000478-200202000-00001. [DOI] [PubMed] [Google Scholar]
- 30.Ma FH, Zhao SH, Qiang JW, et al. MRI appearances of mucinous borderline ovarian tumors: Pathological correlation. J Magn Reson Imaging. 2014 doi: 10.1002/jmri.24408. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
- 31.Vargas HA, Barrett T, Sala E. MRI of ovarian masses. J Magn Reson Imaging. 2013;37:265–81. doi: 10.1002/jmri.23721. [DOI] [PubMed] [Google Scholar]
- 32.Bent CL, Sahdev A, Rockall AG, et al. MRI appearances of borderline ovarian tumours. Clin Radiol. 2009;64:430–38. doi: 10.1016/j.crad.2008.09.011. [DOI] [PubMed] [Google Scholar]
- 33.Bazot M, Haouy D, Darai E, et al. Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours? Clin Radiol. 2013;68:e1–8. doi: 10.1016/j.crad.2012.08.021. [DOI] [PubMed] [Google Scholar]
- 34.Donaldson ES, van Nagell JR, Jr, Pursell S, et al. Multiple biochemical markers in patients with gynecologic malignancies. Cancer. 1980;45:948–53. doi: 10.1002/1097-0142(19800301)45:5<948::aid-cncr2820450519>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
- 35.Karaferic A, Jovanovic D, Jelic S. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. J BUON. 2009;14:635–39. [PubMed] [Google Scholar]
- 36.Ito K. CA19-9 in mature cystic teratoma. Tohoku J Exp Med. 1994;172:133–38. doi: 10.1620/tjem.172.133. [DOI] [PubMed] [Google Scholar]
- 37.Emin U, Tayfun G, Cantekin I, et al. Tumor markers in mature cystic teratomas of the ovary. Arch Gynecol Obstet. 2009;279:145–47. doi: 10.1007/s00404-008-0688-2. [DOI] [PubMed] [Google Scholar]
- 38.Cho HY, Kim K, Jeon YT, et al. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer – CA19-9 level in teratoma. Med Sci Monit. 2013;19:230–35. doi: 10.12659/MSM.883865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009;100:195–99. doi: 10.1111/j.1349-7006.2008.01022.x. [DOI] [PMC free article] [PubMed] [Google Scholar]